News 
 Research 
 Teaching 
 Diagnostic 
 Informations
 Collaborations
 Links
  Home  <  Research  <  A. Telenti Access PlanSitemapPrint  www.unil.ch  www.chuv.ch
Répondant du site:
imu.info@chuv.ch

Amalio Telenti Lab

Amalio Telenti, MD-PhD, Full Professor
++41 (0)21 314 4097
++41 (0)79 556 0751
amalio.telenti@chuv.ch

 

Research topics

Genetics of Human susceptibility to HIV infection

Humans are not equal in terms of susceptibility to infection to HIV, or in the rate of disease progression. This is evidenced by the identification of individuals that remain seronegative despite of multiple exposures to HIV-infected partners, and by the existence of the so called «long-term progressors».

Our laboratory studies the genetic variants that are associated with these differences in susceptibility. Various approaches are currently used:

  1. Genome-wide association studies.
  2. Exome sequencing.
  3. Transcriptome analysis.
  4. Genome evolutionary analysis using primate genomes (Ensembl57) and the 1000 Genome project.
  5. Evolution of antiretroviral restriction genes: analysis of presimian genes and reconstruction of ancestral host genes and endogenous retroviruses.
  6. Systems biology approach to understanding the life cycle of the virus in the infected cell.

Pharmacogenetics of antiretroviral agents

There is considerable variation in the response to antiretroviral drugs among individuals. This concerns both the interindividual differences in pharmacokinetics, and in toxicity. Various approaches are currently used:

  1. Analysis of genetic variation in ADME (absorption, distribution, metabolism and excretion) genes.
  2. Analysis of genetic variation in genes involved in lipid metabolism, cardiovascular disease, bone disease and diabetes to investigate the basis of metabolic disorders associated with use of specific antiretroviral agents.
  3. Translational research to move validated markers to the clinics.

These projects are performed with support of the Swiss National Science Foundation, and in the setting of the Swiss HIV Cohort Study, which includes more than 6000 individuals who have provided consent for genetic analysis.

Current lab members
Name Position Contact
Sara Colombo Pharm, PhD, Euro CHAVI coordinator sara.colombo@chuv.ch
Margalida Rotger Pharm, PhD, Post-doc margalida.rotger@chuv.ch
Rubin Lubomirov MD, Post-doc rubin.lubomirov@chuv.ch
Joke Snoeck PhD, Post-doc joke.snoeck@chuv.ch
Julia di Lulio PhD student Julia.Di-Iulio@chuv.ch
Nadia Rahm PhD student nadia.rahm@chuv.ch
Raquel Martinez Technician raquel.martinez@chuv.ch
Miguel Munoz Technician miguel.munoz@chuv.ch

 

Selected publications


2010
1: Lubomirov R, di Iulio J, Fayet A, Colombo S, Martinez R, Marzolini C, Furrer H, Vernazza P, Calmy A, Cavassini M, Ledergerber B, Rentsch K, Descombes P, Buclin T, Decosterd LA, Csajka C, Telenti A; the Swiss HIV Cohort Study.
    ADME pharmacogenetics: investigation of the pharmacokinetics of the antiretroviral agent lopinavir coformulated with ritonavir.
Pharmacogenet Genomics. 2010 Feb 4. [Epub ahead of print]
2: Rotger M, Dang KK, Fellay J, Heinzen EL, Feng S, Descombes P, Shianna KV, Ge D, Günthard HF, Goldstein DB, Telenti A; The Swiss HIV Cohort Study and the Center for HIV/AIDS Vaccine Immunology.
    Genome-Wide mRNA Expression Correlates of Viral Control in CD4+ T-Cells from HIV-1-Infected Individuals
PLoS Pathog 6(2): e1000781. doi:10.1371/journal.ppat.1000781
3: Specht A, Telenti A, Martinez R, Fellay J, Bailes E, Evans DT, Carrington M, Hahn BH, Goldstein DB, Kirchhoff F.
    Counteraction of HLA-C-mediated immune control of HIV-1 by Nef.
Virol. 2010 May 12. [Epub ahead of print]
4: de Bakker PI, Telenti A.
    Infectious diseases not immune to genome-wide association.
Nat Genet. 2010 Sep;42(9):731-2.

2009
1: Arab-Alameddine M, Di Iulio J, Buclin T, Rotger M, Lubomirov R, Cavassini M, Fayet A, Décosterd L, Eap C, Biollaz J, Telenti A, Csajka C.
    Pharmacogenetics-Based Population Pharmacokinetic Analysis of Efavirenz in HIV-1-Infected Individuals.
Clin Pharmacol Ther. 2009 Feb 18.
2: Fellay J, Ge D, Shianna KV, Colombo S, Ledergerber B, Cirulli ET, Urban TJ, Zhang K, Gumbs CE, Smith JP, Castagna A, Cozzi-Lepri A, De Luca A, Easterbrook P, Günthard HF, Mallal S, Mussini C, Dalmau J, Martinez-Picado J, Miro JM, Obel N, Wolinsky SM, Martinson JJ, Detels R, Margolick JB, Jacobson LP, Descombes P, Antonarakis SE, Beckmann JS, O'Brien SJ, Letvin NL, McMichael AJ, Haynes BF, Carrington M, Feng S, Telenti A, Goldstein DB; NIAID Center for HIV/AIDS Vaccine Immunology (CHAVI).
    Common genetic variation and the control of HIV-1 in humans.
PLoS Genet. 2009 Dec;5(12):e1000791.
3: Iulio JD, Fayet A, Arab-Alameddine M, Rotger M, Lubomirov R, Cavassini M, Furrer H, Günthard HF, Colombo S, Csajka C, Eap CB, Decosterd LA, Telenti A; the Swiss HIV Cohort Study.
    In vivo analysis of efavirenz metabolism in individuals with impaired CYP2A6 function.
Pharmacogenet Genomics. 2009 Feb 20.
4: Martin O, Valsesia A, Telenti A, Xenarios I, Stevenson BJ.
    AssociationViewer: a scalable and integrated software tool for visualization of large-scale variation data in genomic context.
Bioinformatics. 2009 Mar 1;25(5):662-3.
5: Ortiz M, Guex N, Patin E, Martin O, Xenarios I, Ciuffi A, Quintana-Murci L, and Telenti A.
    Evolutionary Trajectories of Primate Genes Involved in HIV Pathogenesis
Molecular Biology and Evolution
6: Rotger M, Bayard C, Taffé P, Martinez R, Cavassini M, Bernasconi E, Battegay M, Hirschel B, Furrer H, Witteck A, Weber R, Ledergerber B, Telenti A, and Tarr PE.
    Contribution of Genome-Wide Significant Single Nucleotide Polymorphisms and Antiretroviral Therapy to Dyslipidemia in HIV-Infected Individuals - A Longitudinal Study
Circulation: Cardiovascular Genetics. 2009
7: Telenti A.
    HIV-1 host interactions: integration of large-scale datasets.
F1000 Biology Reports 2009, 1:71 (doi: 10.3410/B1-71)
8: Thomas R, Apps R, Qi Y, Gao X, Male V, O'hUigin C, O'Connor G, Ge D, Fellay J, Martin JN, Margolick J, Goedert JJ, Buchbinder S, Kirk GD, Martin MP, Telenti A, Deeks SG, Walker BD, Goldstein D, McVicar DW, Moffett A, Carrington M.
    HLA-C cell surface expression and control of HIV/AIDS correlate with a variant upstream of HLA-C.
Nat Genet. 2009 Dec;41(12):1290-4.
9: Urban TJ, Weintrob AC, Fellay J, Colombo S, Shianna KV, Gumbs C, Rotger M, Pelak K, Dang KK, Detels R, Martinson JJ, O'Brien SJ, Letvin NL, McMichael AJ, Haynes BF, Carrington M, Telenti A, Michael NL, Goldstein DB.
    CCL3L1 and HIV/AIDS susceptibility.
Nat Med. 2009 Oct;15(10):1110-2.

2008
1: Ge D, Zhang K, Need AC, Martin O, Fellay J, Urban TJ, Telenti A, Goldstein DB.
    WGAViewer: Software for genomic annotation of whole genome association studies.
Genome Res. 2008 Apr;18(4):640-3.
2: Goldschmidt V, Ciuffi A, Ortiz M, Brawand D, Muñoz M, Kaessmann H, Telenti A.
    Anti-Retroviral Activity of Ancestral TRIM5 (alpha)
J Virol. 2008 Mar;82(5):2089-96.
3: Kazadi K, Loeuillet C, Deutsch S, Ciuffi A, Muñoz M, Beckmann JS, Moradpour D, Antonarakis SE, Telenti A.
    Genomic determinants of the efficiency of internal ribosomal entry sites of viral and cellular origin.
Nucleic Acids Res. 2008 Dec;36(21):6918-25.
4: Loeuillet C, Deutsch S, Ciuffi A, Robyr D, Taffé P, Muñoz M, Beckmann JS, Antonarakis SE, Telenti A.
    In Vitro Whole-Genome Analysis Identifies a Susceptibility Locus for HIV-1.
PLoS Biol. 2008 Feb 19;6(2):e32
5: Ortiz M, Kaessmann H, Zhang K, Bashirova A, Carrington M, Quintana-Murci L, Telenti A.
    The evolutionary history of the CD209 (DC-SIGN) family in humans and non-human primates.
Genes Immun. 2008 Sep;9(6):483-92.
6: Telenti A, Zanger UM.
    Pharmacogenetics of Anti-HIV Drugs.
Annu Rev Pharmacol Toxicol. 2008 Feb 10;48:227-256

2007
1: Arnedo M, Taffé P, Sahli R, Furrer H, Hirschel B, Elzi L, Weber R, Vernazza P, Bernasconi E, Darioli R, Bergmann S, Beckmann JS, Telenti A, Tarr PE; Swiss HIV Cohort Study
    Contribution of 20 single nucleotide polymorphisms of 13 genes to dyslipidemia associated with antiretroviral therapy.
Pharmacogenet Genomics. 2007 Sep;17(9):755-64.
2: Butticaz C, Michielin O, Wyniger J, Telenti A, Rothenberger S
    Silencing of both {beta}-TrCP1 and HOS ({beta}-TrCP2) Is Required To Suppress Human Immunodeficiency Virus Type 1 Vpu-Mediated CD4 Down-Modulation.
J Virol. 2007 Feb;81(3):1502-5.
3: Fellay J, Kevin V. Shianna, Dongliang Ge, Sara Colombo, Bruno Ledergerber, Mike Weale, Kunlin Zhang, Curtis Gumbs, Antonella Castagna, Andrea Cossarizza, Alessandro Cozzi-Lepri, Andrea De Luca, Philippa Easterbrook, Patrick Francioli, Simon Mallal, Javier Martinez-Picado, José M. Miro, Niels Obel, Jason P. Smith, Josiane Wyniger, Patrick Descombes, Stylianos E. Antonarakis, Norman L. Letvin, Andrew J. McMichael, Barton F. Haynes, Amalio Telenti, David B. Goldstein
    A Whole-Genome Association Study of Major Determinants for Host Control of HIV-1
Science. 2007 Aug 17;317(5840):944-7.
4: Loeuillet C, Weale M. Deutsch S, Rotger M. Soranzo N, Wyniger J, Lettre G, Dupré Y, Thuillard D, Beckmann JS, Antonarakis SE, Goldstein DB, Telenti A.
    Promoter polymorphisms and allelic imbalance in ABCB1 expression.
Pharmacogenet Genomics. 2007 Nov;17(11):951-9.
5: Lubomirov R, Csajka C, Telenti A.
    ADME pathway approach for pharmacogenetic studies of anti-HIV therapy.
Pharmacogenomics. 2007 Jun;8(6):623-633.
6: Martin MP, Qi Y, Gao X, Yamada E, Martin JN, Pereyra F, Colombo S, Brown EE, Shupert WL, Phair J, Goedert JJ, Buchbinder S, Kirk GD, Telenti A, Connors M, O'Brien SJ, Walker BD, Parham P, Deeks SG, McVicar DW, Carrington M.
    Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1.
Nat Genet. 2007 Jun;39(6):733-40. Epub 2007 May 13
7: Rotger M, Saumoy M, Zhang K, Flepp M, Sahli R, Decosterd L, Telenti A; Swiss HIV Cohort Study
    Partial deletion of CYP2B6 owing to unequal crossover sith CYP2B7.
Pharmacogenet Genomics. 2007 Oct;17(10):885-90.
8: Rotger M, Tegude H, Colombo S, Cavassini M, Furrer H, Decosterd L, Blievernicht J, Saussele T, Gunthard HF, Schwab M, Eichelbaum M, Telenti A, Zanger UM
    Predictive Value of Known and Novel Alleles of CYP2B6 for Efavirenz Plasma Concentrations in HIV-infected Individuals.
Clin Pharmacol Ther. 2007 Apr;81(4):557-66.
9: Zhang KL, Mangeat B, Ortiz M, Zoete V, Trono D, Telenti A, Michielin O.
    Model Structure of Human APOBEC3G.
PLoS ONE. 2007 Apr 18;2:e378.

2006
1: Amalio Telenti and David B. Goldstein
    Genomics meets HIV.
Nat Rev Microbiol. 2006 Nov;4(11):865-73.
2: Bashirova AA, Bleiber G, Qi Y, Hutcheson H, Yamashita T, Johnson RC, Cheng J, Alter G, Goedert JJ, Buchbinder S, Hoots K, Vlahov D, May M, Maldarelli F, Jacobson L, O'brien SJ, Telenti A, Carrington M.
    Consistent effects of TSG101 genetic variability on multiple outcomes of exposure to human immunodeficiency virus type 1.
J Virol. 2006 Jul;80(14):6757-63
3: Goldschmidt V, Bleiber G, May M, Martinez R, Ortiz M, Telenti A; The Swiss HIV Cohort Study.
    Role of common human TRIM5alpha variants in HIV-1 disease progression.
Retrovirology. 2006 Aug 22;3:54
4: Ortiz M, Bleiber G, Martinez R, Kaessmann H, Telenti A
    Patterns of evolution of host proteins involved in retroviral pathogenesis.
Retrovirology. 2006 Feb 7;3:11


Last Update on 31.08.2010 - Publication credits - Legal information

Search
 Rechercher